TIL Excellence

Tumor-infiltrating lymphocytes (TILs)

Transparent overview of the Sheba protocol developed under Professor Schachter based on NCI experience (Prof. S. Rosenberg).

Why it matters

TIL therapy liberates a patient’s own T-cells, multiplies them in GMP suites, and reinfuses them to fight resistant melanoma.

Clinical evidence

Response rates: 30-50% with 25% being durable remissions, even after PD-1 failure. positioning TILs as a critical salvage option.

Treatment console

Key vitals from Ella Lemelbaum's adoptive cell therapy lab.

30-50% Overall response rate
25% Durable disease control
NIH + EU Active collaborations

Protocol stages

Each module is executed inside a GMP environment with surgical, cellular, and inpatient teams on a synchronized clock.

01

Surgical harvest of an active metastasis with skilled oncology surgeons.

02

Laboratory expansion using IL-2 to reach billions of cells.

03

Lymphodepletion with fludarabine/cyclophosphamide to clear immunologic space.

04

Reinfusion plus high-dose IL-2 support under close inpatient monitoring.